Building core strength through financial strategy
This article was originally published in Scrip
Executive Summary
The CRO industry is full to the brim with private equity investment, with companies such as PRA International, ReSearch Pharmaceutical Services (RPS), INC Research, Medpace, Chiltern International and Theorem Clinical Research (formerly Omnicare Clinical Research) all benefiting from the investment injections of the cash rich. However, one CRO has been busily reversing this strategy, by investing in biopharma companies, for the last decade.